Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Miconazole + hydrocortisone is a topical combination drug used primarily to treat skin infections, including irritant diaper dermatitis and other fungal skin conditions. It combines miconazole, an imidazole antifungal that inhibits the enzyme CYP450 14α-lanosterol demethylase in fungi, disrupting ergosterol synthesis and compromising cell membrane integrity, with hydrocortisone, a corticosteroid that reduces inflammation by suppressing leukocyte migration and reversing increased capillary permeability. The combination provides both antifungal action (from miconazole) and anti-inflammatory relief (from hydrocortisone), leading to rapid symptomatic improvement in pruritus and inflammation associated with dermatophyte or yeast infections[1][5][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on miconazole + hydrocortisone.